Research Paper Volume 11, Issue 16 pp 6053—6068

LINC01198 promotes proliferation and temozolomide resistance in a NEDD4-1-dependent manner, repressing PTEN expression in glioma

Figure 2. LINC01198 promotes glioma proliferation and resistance to temozolomide. (A) LINC01198 expression was examined in several glioma cell lines, normal brain tissues, and glioma tissues using qRT-PCR. GAPDH was used as a control for loading. (B and C) LINC01198 expression in glioma cells was modified by shRNA interference and cDNA transfection. (D) Growth curve showing the proliferation activities of glioma cell transfectants in vitro. (E) IC50 value of temozolomide on glioma cells. Cells were treated with different concentrations of temozolomide for 72 hours. (F) Antitumor effect of temozolomide on glioma xenografts in an established model. (G) The data were expressed as percentage inhibition of tumor growth. (H) The survival time of mice bearing glioma subcutaneous xenograft received temozolomide therapy. Data are presented as the mean ± SD, n=3. *P < 0.05, **P < 0.01.